The glucagon arm: the differentiator
The glucagon arm is what makes retatrutide a triple agonist rather than a second tirzepatide.
The receptor that burns energy instead of just curbing intake
The glucagon arm is what makes retatrutide a triple agonist rather than a second tirzepatide. Glucagon is best known for raising blood sugar, which sounds like the wrong direction entirely. The stated reason to add it is energy expenditure: in the discovery work, body weight loss was augmented by adding glucagon-receptor-mediated increases in energy expenditure to the calorie-intake reduction the two incretin arms drive.
This unit takes the arm as far as the evidence goes and stops there. The energy-expenditure figure is a mouse figure. The liver mechanism is a hypothesis the papers phrase as a maybe. What is measured in people is the outcome: the liver-fat result, the lipid changes, and the net glucose effect.
Key terms
Where the glucagon arm acts
Glucagon works through the liver, but its metabolic reach extends to whole-body energy use. Glucagon receptor agonists make the liver build new glucose and release stored glucose, and they also raise energy expenditure, promote fat burning and improve how the liver handles fat. To understand the arm, you have to separate its two faces: the glucose-raising effect that must be managed, and the energy-expenditure and fat-burning effects that retatrutide wants. Mapping the sites makes that split concrete.
This dual nature is the whole story of the glucagon arm. Get the balance right and you gain a powerful fat-burning, energy-raising effect. Get it wrong and blood sugar drifts up. Retatrutide's design is a bet that the balance can be held, and the phase 2 glucose data suggest it largely is.
AdvancedWhy glucagon is not a contradiction
It feels paradoxical to engage a glucose-raising hormone in an anti-diabetes drug. What the trials answer is the net question, not the mechanism: in the phase 2 diabetes trial HbA1c fell by 2.02 percentage points at 24 weeks on 12 mg against 0.01 on placebo. Whatever the glucagon arm adds to glucose, the incretin arms more than cover it. The trials measure that net result, not the two forces separately.